PharmaEssentia Announces Updated NCCN Clinical Practice Guidelines Include ropeginterferon alfa-2b-njft (BESREMi®) for Treatment of Essential Thrombocythemia (ET), by . PharmaEssentia USA Corporation.

Centering their discussion on cornerstone therapies, expert hematologist-oncologists consider the treatment paradigms of essential thrombocythemia and polycythemia vera. Rami Komrokji, M.D.: Once we ...

Overexpression of the Polycythemia Rubra Vera-1 Gene in Essential Thrombocythemia Authors: Luciana Teofili, Maurizio Martini, Myriam Luongo, Antonella Di Mario, Giuseppe Leone, Valerio De Stefano, and ...

A recent study identified trends in blood counts, but did not find statistically significant associations between achieving hematological remission and clinical outcomes in polycythemia vera (PV) or ...

Elevated absolute eosinophil counts and absolute basophil counts (ABC) are associated with reduced overall survival in essential thrombocythemia. In polycythemia vera, higher ABC correlates with ...

Taiwan’s PharmaEssentia has committed $46 million to build a Puerto Rico drug manufacturing facility to serve the U.S. market ...

While taking testosterone-based HRT, your doctor will monitor your bloodwork for signs of polycythemia. If found, several treatment options are available. Testosterone is responsible for many body ...

The blood you don’t need could be exactly what someone else is praying for. It sounds inconceivable, yet for patients requiring frequent therapeutic phlebotomy—blood removal as treatment—this blood is ...

Overexpression of the Polycythemia Rubra Vera-1 Gene in Essential Thrombocythemia. If you have the appropriate software installed, you can download article citation data to the citation manager of ...